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Abstract
Introduction: Neuropsychiatric systemic lupus erythematosus is often clinically challenging to diagnose, treat and 
monitor. Although brain magnetic resonance imaging is frequently performed before lumbar puncture in neuropsychiatric 
systemic lupus erythematosus, it is not clear from the literature whether specific brain magnetic resonance imaging 
findings are associated with distinct clinical features of neuropsychiatric systemic lupus erythematosus.
Methods: We conducted a systematic review and meta-analysis on published studies of neuropsychiatric systemic lupus 
erythematosus including brain magnetic resonance imaging and the 1999 American College of Rheumatology-defined 
clinical neuropsychiatric systemic lupus erythematosus syndromes to determine their relationship. Pooled prevalence 
and risk ratio for distinct neuropsychiatric systemic lupus erythematosus associations were determined with 95% 
confidence intervals.
Results: Of 821 studies screened, 21 fulfilled inclusion criteria. A total of 818 participants were evaluated (91% female) with 
1064 neuropsychiatric systemic lupus erythematosus episodes assessed. Neuropsychiatric systemic lupus erythematosus 
features included headache (24%), seizures (19%), cerebrovascular disease (18%), cognitive dysfunction (15%) and acute 
confusional state (14%). Normal magnetic resonance imaging was significant for anxiety disorder (risk ratio: 9.00; 95% 
confidence interval: 2.40, 33.79), autonomic disorder (risk ratio: 7.00; 95% confidence interval: 0.51, 96.06) and plexopathy 
(risk ratio: 5.00; 95% confidence interval: 0.81, 31.00). Highest risk ratio of neuropsychiatric systemic lupus erythematosus 
syndrome with abnormal magnetic resonance imaging was observed for cerebrovascular disease (risk ratio: 0.15; 95% 
confidence interval: 0.10, 0.24) and demyelination (risk ratio: 0.11; 95% confidence interval: 0.02, 0.72).
Conclusion: Normal magnetic resonance imaging in neuropsychiatric systemic lupus erythematosus was the most 
significant correlate from our meta-analysis for psychological symptoms including anxiety and peripheral nerve features 
of autonomic disorder and plexopathy. The main abnormal brain magnetic resonance imaging correlates included 
cerebrovascular disease and demyelination. Brain magnetic resonance imaging correlates poorly with neuropsychiatric 
systemic lupus erythematosus features, and specific clinical symptoms should be the main determinants of performing 
magnetic resonance imaging rather than presence of neuropsychiatric systemic lupus erythematosus per se.
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Introduction
Systemic lupus erythematosus (SLE) is a chronic auto-
immune disorder that affects multiple organ systems with 
inflammation, immune complex deposition and vasculopa-
thy as the primary pathological findings. The disease preva-
lence of SLE varies worldwide from 13 to 51 cases per 
100,000 and has been reported as increasing due to 
improvements in survival.1,2 The condition shows a marked 
female predominance, being approximately nine times as 
common in women than in men.3–5
Neuropsychiatric systemic lupus erythematosus 
(NPSLE) is characterised by diverse syndromes affecting 
both the central and peripheral nervous systems (CNS and 
PNS). Features can range from mild headaches to more 
severe manifestations, such as epilepsy, cerebrovascular 
disease, psychiatric disorders, cranial and peripheral neu-
ropathies.6,7 NPSLE features can be difficult to distinguish 
from other diseases, while the heterogeneity of the condi-
tion can make the conduct of research challenging. 
Objective and subjective criteria have been used for inclu-
sion in studies, while variations in baseline patient charac-
teristics and duration of observation may add to the 
inconsistency of the reported data.6,8,9 The prevalence of 
neuropsychiatric NPSLE varies from 31% to 91%.9
Several processes have been implicated in the pathogen-
esis of NPSLE. Local release of inflammatory cytokines, 
autoantibody-mediated response to CNS components and 
formation of immune complexes, resulting in cerebrovas-
culopathic changes and neuronal injury may all be key.10–13 
The presence of antiphospholipid antibodies may exacer-
bate the disease, increasing the risk of thrombotic arterial or 
venous disease and accelerated atherosclerosis.14
Diagnosis and management options are dependent on 
the underlying syndrome. The adoption of cerebrospinal 
fluid (CSF) analysis, electroencephalography (EEG) and 
neuroimaging techniques has been recommended by the 
European League Against Rheumatism (EULAR) task 
force for the diagnosis of NPSLE or to exclude concomi-
tant illnesses, infection or drug side effects.15 Despite this, 
correct attribution of neuropsychiatric events to NPSLE 
remains a clinical challenge as there is no gold standard 
diagnostic test. Glucocorticoids, immune-modulatory 
drugs and anticoagulants/anti-platelets have been used 
empirically in the treatment of inflammatory and vasculo-
pathic causes of NPSLE. However, clinical trial data on 
these interventions remain sparse.
Although the prognosis of SLE has improved consider-
ably in recent times, NPSLE still remains a major cause of 
morbidity and mortality. A recent study reported a 19% 
mortality rate, with infection and NPSLE attributed as the 
leading causes of death in SLE patients.16 Despite the fre-
quent occurrence of brain involvement in SLE, our knowl-
edge of NPSLE syndromes and their association with 
imaging findings remains speculative. The American 
College of Rheumatology (ACR) published a consensus for 
the classification, nomenclature and case definitions for 19 
distinct neuropsychiatric syndromes in 1999, with the aim 
of facilitating research.7 The criteria have been subject to 
debate in several studies, some of which have questioned 
the low specificity for diffuse syndromes such as headache, 
cognitive dysfunction and minor psychiatric disorders 
commonly reported in chronic diseases generally.8,17,18
In a meta-analysis conducted in 2011, headache (12%) 
was determined as the most prevalent syndrome, followed 
by mood disorder (7%), seizure disorder (7%), cognitive 
dysfunction (7%) and cerebrovascular disease (CVD) (5%). 
PNS syndromes such as autonomic disorder and Guillain–
Barré syndrome (GBS) (<0.1%) were rarely reported.9 
Unterman et al.9 reported that Asians (72%), Caucasians 
(16%) and Hispanics (4%) were the most frequently 
affected ethnicities.
Brain magnetic resonance imaging (MRI) remains the 
most commonly used imaging technique to assist in the 
diagnosis of NPSLE due to its wide availability. Recently, 
more advanced imaging tools, such as the MRI methods of 
magnetisation transfer imaging (MTI), diffusion-weighted 
imaging (DWI) and diffusion tensor imaging (DTI), and 
methods using radioactive tracers, such as positron emis-
sion tomography (PET) and single-photon emission com-
puted tomography (SPECT), have been increasingly 
studied.15,19 Furthermore, the EULAR task force has rec-
ommended the use of advanced imaging in cases of normal 
MRI findings in patients with NPSLE, providing further 
rationale to specifically assess MRI. Table 1 lists the differ-
ent imaging modalities, their descriptions and common 
findings. SPECT studies have demonstrated a higher sensi-
tivity in patients with diffuse neurological involvement 
compared with MRI.19,26,27 However, the cost and limited 
availability of SPECT and PET and the need for better 
standardisation and validation for interpretation of 
advanced quantitative MRI protocols have prevented their 
establishment in routine clinical practice thus far.15,28,29 For 
this reason, the focus of our study was conventional MRI.
The aim of this systematic review and meta-analysis 
was to assess whether the clinical NPSLE syndromes 
defined by the 1999 ACR criteria are linked to distinct brain 
MRI abnormality. This is important as any brain MRI 
Amin et al. 3
association with specific NPSLE features could potentially 
aid clinicians in diagnosing NPSLE with more confidence 
and link individual NPSLE syndromes with structural or 
pathologic changes such as thrombosis and CVD.
Materials and methods
Search strategy
The electronic databases PubMed, MEDLINE (via Ovid), 
Embase (via Ovid) and the Cochrane Library were searched 
from their inception to November 2015. The grey literature 
and trial registries OpenGrey, WHO International Clinical 
Trials Registry Platform, Current Controlled Trials and the 
United States National Institute of Health Trials Registry 
were also searched from inception to November 2015 for 
any additional papers omitted from the principle search. The 
terms used for the MEDLINE search were as follows: sys-
temic lupus erythematosus, neuropsychiatry/neurologic dis-
ease, lupus erythematosus, neuropsychiatric systemic lupus 
erythematosus, lupus vasculitis, CNS, nuclear magnetic 
resonance imaging, magnetic resonance imaging and MRI.
Study eligibility and identification
Papers were eligible if they provided data on the prevalence 
of clinical syndromes for NPSLE and presented corre-
sponding brain MRI imaging data to assess the prevalence 
for individual clinical syndromes. Papers were excluded if 
they were reviews, case reports, letters to the editor or stud-
ies not published in English or assessing human subjects. 
Studies were included irrespective of the number of cases 
of NPSLE evaluated in individual studies due to the rela-
tive rarity of NPSLE1,2 and to minimise the risk of small 
sample size publication bias from impacting on the review’s 
analysis. The results of the search strategy were reviewed 
by two authors (O.A., A.K.). Each title and abstract was 
assessed against the eligibility criteria. The full texts were 
obtained for those papers which were thought to be poten-
tially eligible. The same two reviewers assessed the eligi-
bility of each full text, and if they met the criteria, they were 
included in the review. In our search, we were unable to 
include comparisons of brain MRI changes in patients 
without SLE and without neuropsychiatric manifestations, 
as we were unable to find studies of this kind and we recog-
nise this as a limitation. We were also unable to compare 
MRI findings between NPSLE versus SLE patients or SLE 
patients versus healthy controls, as we were unable to find 
any studies outlining these specified comparisons. Instead, 
we classified SLE patients based on the outcomes, that is, 
having normal versus abnormal MRI scans and then com-
pare each group based on individual NPSLE syndrome. 
There are two issues with this approach. First, the defini-
tion of normal MRI scan is more difficult to establish and 
more subjective. Second, there is no causal relationship or 
correlation between NPSLE syndrome and MRI finding 
which can be concluded. Third, there is a chance that some 
of the NPSLE syndromes may (e.g. anxiety) develop later 
Table 1. Summary of imaging modalities, their descriptions and common findings in NPSLE.
Imaging modality Findings in NPSLE Reference
T1-weighted (T1w) MRI Atrophy Bertsias et al.15
T2-weighted (T2w) MRI Multifocal white matter hyperintensities (WMHs) in 
subcortical, periventricular and frontoparietal regions; 
infarcts
Zardi et al.,19 Luyendijk et al.20 
and Jennings et al.21
Fluid-attenuated inversion recovery 
(FLAIR)
Subcortical and periventricular WMH lesions; infarcts Luyendijk et al.,20 Yaniv et al.22 
and Ercana et al.23
Magnetisation transfer imaging (MTI) Demyelination, ischaemia and oedema major 
contributors to changes in magnetisation transfer 
ratio (MTR) and reduced histogram peak heights
Zardi et al.,19 Ercana et al.23 and 
Bosma et al.24
Magnetic resonance spectroscopy 
(MRS)
Reduced NAA levels thought to reflect neuronal 
injury/death
Zardi et al.,19 Yaniv et al.22 and 
Lim et al.25
Diffusion-weighted imaging (DWI) Apparent diffusion coefficient (ADC) of water 
protons raised due to loss of tissue integrity in grey 
matter (GM) and white matter (WM)
Zardi et al.19 and Yaniv et al.22
Diffusion tensor imaging (DTI) Reduced FA associated with reduction in axonal 
integrity in WM
Zardi et al.,19 Yaniv et al.22 and 
Govoni et al.26
Perfusion-weighted imaging (PWI) Demonstrates areas of hypoperfusion, though with 
lower sensitivity than SPECT
Govoni et al.26
Positron emission tomography (PET) Hypometabolism most commonly detected in 
parieto-occipital region indicating reduced neuronal 
density/perfusion
Zardi et al.19 and Govoni et al.26
Single-photon emission computed 
tomography (SPECT)
Diffuse, focal or multifocal areas of hypoperfusion in 
frontal, parietal and temporal lobes
Zardi et al.,19 Govoni et al.26 
and Zhang et al.27
NPSLE: neuropsychiatric systemic lupus erythematosus; NAA: N-acetylaspartate; MRI: magnetic resonance imaging; FA: fractional anisotropy.
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despite a normal structural MRI scan. Our results therefore 
need to be interpreted with these limitations in mind.
Data extraction and appraisal
Data were extracted from each included paper by two 
reviewers (O.A., A.K.). This was performed indepen-
dently, with the results verified by each other. Data which 
were extracted onto our data extraction form included the 
following: country of study, study design, MRI imaging 
sequence, number of patients MRI assessed, number of 
syndromes detected, mean and range of ages of subjects, 
gender of subjects, duration of NPSLE, age of onset, dis-
ease activity, clinical syndromes detected, prevalence of 
syndromes within the cohort, prevalence of normal and 
abnormal MRI findings and prevalence of specific MRI 
findings. The MRI findings extracted included the follow-
ing: white matter hyperintensities, grey matter hyperin-
tensities, parenchymal defects, cerebral atrophy, large 
vessel disease, small vessel disease, inflammatory lesions, 
microbleeds, recent infarct, lacunes, vascular signs, 
intracranial haemorrhage, focal oedema, diffuse cerebral 
oedema, punctuate focal lesions, periventricular lesion 
and microcalcification.
Two reviewers (O.A., A.K.) independently assessed the 
quality of each included paper using a modified Critical 
Appraisal Skills Programme (CASP)30 checklist. This was 
chosen as it is a valid tool which consists of a set of ques-
tions designed to evaluate the internal and external validi-
ties of clinical studies. The results from each reviewer were 
evaluated to gain a consensus on the final quality assess-
ment judgement.
Data analysis
An assessment of study heterogeneity was derived through 
assessment of the data extraction table. Where population, 
study design, data collection and MRI investigation were 
considered comparable, a pooled assessment of prevalence 
of clinical syndromes in NPSLE was made. Similarly, an 
assessment of pooled prevalence of MRI features for each 
specific clinical syndrome was made. The risk ratio (RR) 
was determined of detecting an abnormal MRI result com-
pared to normal MRI for people with NPSLE for each indi-
vidual clinical syndrome. For each calculation, pooled 
prevalence was presented as a percentage with 95% confi-
dence intervals (CIs). Similarly, RR was assessed with 95% 
CIs using a random effects model analysis and statistical 
heterogeneity using I2 and χ2 statistical tests. Sensitivity 
analyses were conducted, where appropriate assessing out-
comes, when there were 100 participants or more to mini-
mise the risk of small study effects from impacting on the 
outcome.54 Small sample size publication bias was assessed 
using a funnel plot of the most frequently reported NPSLE 
feature (seizures). All analyses were conducted on RevMan 
(Review Manager version 5.1; Copenhagen: The Nordic 
Cochrane Centre (the Cochrane Collaboration, 2011)) and 
Stata version 12.0 (StataCorp LP, College Station, TX, 
USA).
Results
Search strategy
A summary of the search results is presented in Figure 1. A 
total of 821 citations were identified from the search strat-
egy. Of these, 21 were deemed eligible and included in the 
analysis based on the search criteria.
Study quality assessment
Full assessment of the studies with their total scores is 
shown in Table 2. The results of the CASP appraisal high-
lighted several methodological limitations. First, while 
90% defined the study population and the recruitment 
Figure 1. Flow chart summarising the results of the search 
strategy and the process of study inclusion/exclusion.
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process, only 57% of studies used the 1999 ACR guidelines 
for NPSLE case definitions, with research published prior 
to 1999 relying on clinicians for assessment and definitions 
used. Only 29% enrolled control groups for comparison, 
with either healthy individuals or SLE participants with no 
brain involvement serving as controls. Just 24% of the stud-
ies described blinding of the neuroradiologist to minimise 
bias. The quality of the evidence base was further weak-
ened, as 57% of the studies did not mention any confound-
ing factors. A total of 38% of studies carried out a statistical 
analysis, and 71% described their methods section in suffi-
cient detail.
Characteristics of included studies. In total, 818 individuals 
(745 females/73 males) with 1064 NPSLE clinical syn-
dromes were included and analysed. The study sample’s 
ages ranged from 13.342 to 44.0 years.41 The duration 
from NPSLE diagnosis to MRI was not specified in 16 
papers. In three papers, the duration from NPSLE diagno-
sis to MRI was less than 3 months,31,32,33 it was up to 
1 year in one study,35 while it was a mean 47.1 months in 
another study.46 Disease activity was defined and reported 
in eight studies. This ranged from 4.7 Systemic Lupus 
Erythematosus Disease Activity Index (SLEDAI)38 to 34 
SLEDAI36 and 14.2 British Isles Lupus Activity Group 
(BILAG).46
A variety of MRI investigation descriptions were pro-
vided. In 10 papers, T1, T2 and fluid-attenuated inversion 
recovery (FLAIR) were used;20,21,31,33–36,46,39,40 four studies 
simply stated that MRI was undertaken.37,43–45 Imaging was 
described in individual studies as follows: T1, T2, FLAIR 
and DWI;32 T1, T2, voxel-based morphometry;38 T1, T2, 
FLAIR, SPECT;27 T1, T2, FLAIR, MTI;24 T1, T2, magnetic 
resonance spectroscopy (MRS);25 and MRI, SPECT.42
Five studies were undertaken in the United 
States,21,36,41,44,45 three in Japan,34,35,46 two in South 
Korea,25,32 two from the Netherlands20,24 and two from 
Brazil.38,39 Single studies were undertaken in Turkey,37 
China,27 Poland,40 Canada,42 Germany43 and Spain,33 while 
one study was conducted in both Spain and the United 
Kingdom.31 Nine papers reported retrospective studies, 
while seven were prospective studies. It was unclear 
whether the studies were retrospective or prospective in 
five instances.
Publication bias
Small sample size publication bias was assessed using a 
funnel plot. As represented in Figure 2, for the measure 
with the largest data set (seizures), this produced a 
broadly symmetric funnel plot suggesting low risk of 
publication bias.
Meta-analysis
Prevalence of clinical syndromes in NPSLE. Pooled prevalence 
of clinical syndrome in NPSLE was headache, with a prev-
alence of 23.8% (95% CI: 21.1%–26.9%; N = 818). This 
Figure 2. Funnel plot of small sample publication bias for the assessment of seizures with NPSLE and abnormal compared versus 
normal MRI findings.
RR: Risk ratio; SE: standard error
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was followed by, in order of frequency, seizures (preva-
lence: 18.9%; 95% CI: 16.3%–21.7%; N = 818), CVD 
(prevalence: 17.6%; 95% CI: 15.1%–20.4%; N = 818) and 
cognitive dysfunction (prevalence: 15.3%; 95% CI: 13.0%–
17.9%; N = 818). The least prevalent clinical syndromes 
were myasthenia gravis (prevalence: 0%; 95% CI: 0.0%–
0.01%; N = 712), GBS (prevalence: 0.3%; 95% CI: 0.08%–
1.1%; N = 659), plexopathy (prevalence: 0.9%; 95% CI: 
0.4%–2.0%; N = 659) and polyneuropathy (prevalence: 
1.4%; 95% CI: 0.1%–2.6%; N = 659).
RR of an abnormal MRI finding for individual clinical syndromes 
in NPSLE. A summary of the pooled prevalence of normal 
and abnormal MRI brain findings for each clinical syn-
drome with NPSLE is presented in Table 3. There was vari-
able statistical heterogeneity for each of these analyses 
(Supplementary Table 1). The highest prevalence of nor-
mal MRI brain features for individual clinical syndromes in 
the NPSLE cohort was for anxiety (prevalence: 90%; 95% 
CI: 69.9%–97.2%; N = 20), followed by plexopathy (preva-
lence 83.3%; 95% CI: 43.7%–97.0%: N = 6), cranial 
Table 3. Pooled prevalence of MRI findings by individual clinical feature for people with NPSLE.
NPSLE syndrome Top three MRI features – prevalence (95% CI) (N of study) Normal MRI – 
prevalence (95% CI)
Headache Small vessel disease
48.6 (33.0–64.4) (1)
White matter hyperintensity
34.1 (26.6–42.4) (8)
Grey matter 
hyperintensity
34.1 (26.6–42.4) (8)
48.9 (41.8–56.1) (13)
CVS syndrome Small vessel disease
79.0 (56.7–91.5) (1)
White matter hyperintensity
66.0 (56.1–74.6) (5)
Parenchymal defects
47.4 (35.5–62.7) (2)
13.2 (8.4–20.1) (10)
Seizures White matter hyperintensity
61.5 (52.1–70.1) (11)
Cerebral atrophy
56.0 (46.6–64.9 (11)
Small vessel disease
52.6 (31.7–72.7 (1)
37.7 (30.6–45.5) (18)
Cognitive 
dysfunction
Small vessel disease
78.6 (52.4–92.4) (1)
White matter hyperintensity
72.6 (61.0–81.6) (9)
Cerebral atrophy
45.7 (34.8–57.3) (8)
26.7 (19.1–35.8) (15)
Mood disorders White matter hyperintensity
50.6 (40.1–61.1 (8)
Cerebral atrophy
34.6 (23.2–48.2 (8)
Parenchymal defects
30.8 (12.7–57.6) (3)
49.4 (38.9–60.0) (16)
Myelopathy Small vessel disease
75.0 (30.1–95.4 (1)
White matter hyperintensity
57.1 (25.0–84.2 (2)
Inflammatory lesions
50.0 (18.8–81.2 (2)
35.7 (16.3–61.2) (7)
Anxiety Small vessel disease
33.3 (6.2–79.2) (2)
Cerebral atrophy
33.3 (9.7–70.0) (3)
90.0 (69.9–97.2) (9)
ACS Small vessel disease
66.7 (20.8–98.4) (1)
White matter hyperintensity
56.9 (44.1–68.8) (5)
Infarct (recent)
38.5 (17.7–64.5) (3)
41.1 (31.7–51.1) (11)
Psychosis Infarct (recent)
40.0 (11.8–76.9) (3)
White matter hyperintensity
37.5 (22.9–54.8) (7)
Cerebral atrophy
25.6 (14.8–41.1) (7)
57.9 (42.2–72.1) (12)
Aseptic meningitis Inflammatory lesions
100.0 (34.2–100.0) (2)
Small vessel disease
100.0 (20.7–100.0) (1)
White matter 
hyperintensity
50.0 (23.7–76.3 (4)
55.0 (34.2–74.2) (8)
Demyelinating 
syndrome
White matter hyperintensity
100.0 (56.6–100.0) (2)
Small vessel disease
100.0 (20.7–100.0) (1)
Inflammatory lesions
100.0 (20.7–100.0) (1)
10.0 (1.7–40.1) (3)
Cranial 
neuropathy
White matter hyperintensity
44.4 (24.6–66.3) (3)
Grey matter hyperintensity
15.4 (4.3–42.2) (3)
Infarct (recent)
16.7 (3.0–56.4) (2)
64.0 (44.5–80.0) (6)
Mononeuropathy Small vessel disease
80.0 (37.6–96.4) (1)
White matter hyperintensity
55.6 (26.7–81.1) (3)
Grey matter 
hyperintensity
25.0 (4.6–69.9) (2)
40.0 (16.8–68.7) (4)
Polyneuropathy Grey matter hyperintensity
55.6 (26.7–81.1) (5)
Large vessel disease
50.0 (15.1–85.0) (1)
Small vessel disease
50.0 (15.1–85.0) (1)
22.2 (6.3–54.7) (5)
Plexopathy White matter hyperintensity
25.0 (4.6–69.9) (3)
Grey matter hyperintensity
0.0 (0.0–65.8) (2)
Parenchymal defects
0.0 (0.0–65.8) (2)
83.3 (43.7–97.0) (4)
Movement 
disorder
White matter hyperintensity
83.3 (43.7–97.0) (4)
Grey matter hyperintensity
0.0 (0.0–42.5) (3)
Parenchymal defects
0.0 (0.0–42.5) (3)
20.0 (5.7–51.0) (7)
GBS White matter hyperintensity
50.0 (9.5–90.6) (3)
Grey matter hyperintensity
0.0 (0.0–65.8) (3)
Parenchymal defects
0.0 (0.0–65.8) (3)
50.0 (9.5–90.6) (3)
Myasthenia gravis White matter hyperintensity
0.0 (0.0–0.0) (2)
Grey matter hyperintensity
0.0 (0.0–0.0) (2)
Parenchymal defects
0.0 (0.0–0.0) (2)
0.0 (0.0–0.0) (2)
Autonomic 
disorder
Inflammatory lesions
0.00 (0.00–0.00) (1)
Microbleed
0.00 (0.00–0.00) (1)
n/a 100.0 (43.9–100.0) (2)
NPSLE: neuropsychiatric systemic lupus erythematosus; MRI: magnetic resonance imaging; CI: confidence interval; CVS: cerebrovascular syndrome; 
ACS: acute confusional state; GBS: Guillain–Barré syndrome.
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neuropathy (prevalence: 64.0; 95% CI: 44.5%–80.0%; 
N = 25) and aseptic meningitis (prevalence: 55.0%; 95% 
CI: 34.2%–74.2%; N = 20). When solely assessing analyses 
of over 100 subjects, the highest prevalence of normal MRI 
brain features was for headache (prevalence: 48.9%; 95% 
CI: 41.8%–56.1%; N = 184), seizures (prevalence: 37.7%; 
95% CI: 30.6%–45.5%; N = 159) and cognitive dysfunction 
(prevalence: 26.7%; 95% CI: 19.1%–35.8%; N = 105). 
Seven clinical syndromes demonstrated statistically signifi-
cant association when assessed with RR. CVD, seizures, 
cognitive dysfunction, acute confusional state (ACS), 
demyelinating syndrome and movement disorders all dem-
onstrated a greater risk of demonstrating abnormal MRI 
brain findings in people with NPSLE. Only anxiety was 
shown to have a lower risk of an abnormal MRI brain find-
ing in NPSLE (RR: 9.00; 95% CI: 2.40–33.79; N = 20) 
(Figure 3).
Prevalence of MRI features for individual clinical syndromes in 
NPSLE. The prevalence data for each individual abnormal 
MRI brain feature and the clinical syndrome are presented 
in Table 3. The most prevalent MRI features were white 
matter hyperintensities (WMHs) (34.1%), grey matter 
hyperintensities (GMHs) (22.9%), parenchymal defects 
(6.5%), cerebral atrophy (16.9%) and small vessel disease 
(48.6%). On assessment of the 10 distinct brain MRI 
changes that we evaluated, CVD showed positive MRI 
findings in all categories, the most prevalent of which were 
white matter hyperintensity (66%), small vessel disease 
(79.0%), grey matter hyperintensity (44.8%) and parenchy-
mal defects (47.4%). Headache demonstrated positive MRI 
features in 6 of the 10 categories assessed, with the most 
frequent findings being small vessel disease (48.6%) and 
white matter hyperintensity (34.1%). All the clinical syn-
dromes were assessed for nine MRI abnormalities; 
in several, MRI findings were not observed, including 
myasthenia gravis features (100% MRI scans did not show 
abnormalities), plexopathy (88.9%), movement disorder 
(88.9%), GBS (88.9%), myelopathy (44.4% MRI changes 
not seen), anxiety (66.7%) and mood disorders (33.3%).
Discussion
Despite the presence of NPSLE syndromes with varying 
disease severity, a normal imaging outcome on conven-
tional MRI was frequently observed in our study. The most 
common NPSLE syndromes in patients undergoing MRI 
evaluation in our selected studies were headache (23.8%), 
seizures (18.9%), CVD (17.6%), cognitive dysfunction 
(15.3%), ACS (13.8%) and mood disorders (11.1%). CNS 
manifestations were more frequent than PNS ones (91.3% 
vs 8.7%).
The most significant findings from our meta-analysis 
were the observation of normal brain MRI in a variety of 
clinical syndromes, including psychiatric syndromes such 
as anxiety (RR: 9.00) and PNS features such as autonomic 
disorder (RR: 7.00) and plexopathy (RR: 5.00). Associations 
between abnormal brain MRI and clinical NPSLE syn-
dromes were observed in a broad range of clinical features 
including CVD (RR: 0.15), demyelination (RR: 0.11) and 
seizures (RR: 0.61).
Brain MRI in NPSLE is often conducted as part of the 
clinical workup, especially before performing a lumbar 
puncture. We found a low detection rate of distinct clinical 
NPSLE features correlating with specific brain MRI 
changes. Nevertheless, it is important to take into account 
that patients with objective syndromes such as seizures and 
CVD present with overt symptoms may undergo MRI scans 
sooner, while milder manifestations of subjective syn-
dromes like cognitive dysfunction, mood or anxiety 
Figure 3. Forest plot of risk ratio of an abnormal compared to normal MRI findings for 19 clinical features of NPSLE.
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disorder may not be referred for MRI investigation until 
reaching a clinically severe stage. This reduces the reliabil-
ity of the prevalence values with this possibility leading to 
an under- or over-estimation of some features. Interestingly, 
the EULAR task force recommended MRI investigation 
more urgently in selected syndromes.15 Notably, our meta-
analysis included studies which did not investigate all 19 
NPSLE syndromes. For example, Toyota et al.34 included 
only seizure patients in NPSLE. This may have therefore 
led to selection bias when estimating prevalence values.
The 21 included studies reported inconsistent details of 
MRI lesions in terms of their size, number and locations. 
The radiographic terms used to describe and list these into 
specific groups often differed, as no standard guidelines 
were adhered to. Hence, the resulting wide heterogeneity of 
lesion descriptions in the studies made cross-comparisons 
difficult. It was therefore decided to group them into themes 
of the most recurring terms used, which in our selected 
studies were WMH, GMH and atrophy. The ‘vascular 
lesion’ group consisted of descriptions, which could be 
confidently assigned into this particular category which 
included ‘microbleeds’, ‘infarcts’, ‘lacunar lesions’ and 
‘intracranial haemorrhage’. Any terms recorded, where a 
degree of uncertainty existed over which category they 
would fit into best, were categorised as ‘other’. We found 
that WMHs were consistently the most frequently reported 
abnormality (33.1%–53.3%) among the eight most preva-
lent syndromes, followed by vascular lesions (6.7%–
31.7%), although a considerable overlap between the two is 
likely. Atrophy was also a common feature (6.7%–35.7%), 
while GMHs were less frequent (2.8%–14.4%).
The precise role of distinct MRI lesions in the patho-
physiology of NPSLE remains uncertain. Focal WMH 
lesions have been linked to various non-specific changes 
such as necrosis, reduced neuronal density, inflammatory 
infiltrates and demyelination. An underlying acute infarct 
has been suggested in areas where reduced diffusion was 
observed secondary to cytotoxic oedema, while bilateral 
WMHs are thought to be a sign of chronic hypoperfu-
sion.20 Common sites of WMH lesions are in the frontopa-
rietal region, periventricular and subcortical white matter, 
and their presence has been recorded in both active and 
inactive NPSLE.29,47–49 Although evidence still persists 
that WMHs are not specific to NPSLE, as it was shown in 
SLE without overt neuropsychiatric involvement, they 
were found to be higher in quantity and total volume in 
active and past NPSLE when compared with non-NPSLE 
patient groups.50 Specifically, a correlation between cog-
nitive dysfunction, cerebrovascular syndrome and WMHs 
has been shown in previous studies.31,47
Atrophy is another non-specific radiographic finding in 
NPSLE patients, and many factors have been associated to 
contribute towards it, including disease duration, corticos-
teroid use, advancing age and presence of antiphospholipid 
syndrome (APS).47 However, a recent study found that 
participants with NPSLE had significantly pronounced 
atrophy compared to SLE with no brain involvement and 
healthy controls, after adjusting for age.51 Histopathologic 
correlations for atrophy vary, having been observed in 
patients with diffuse and focal brain injury.36,52,53 Atrophy 
has been found to be significantly associated with cognitive 
dysfunction, seizure disorder and CVD in another study.47
MRI results in other diffuse syndromes such as ACS, 
psychosis and anxiety disorder were investigated by 
Arinuma et al.46 and found to be normal in 52.8% of the 
cases. Another study pointed out that the rate of abnormal 
lesions detected on conventional MRI in diffuse syn-
dromes was not significantly different from SLE patients 
with no neuropsychiatric involvement.50 They concluded 
that while MRI remains sensitive for focal lesions, a com-
bined approach of morphological and functional imaging, 
such as SPECT, would be more helpful in excluding brain 
abnormalities in diffuse syndromes with normal MRI. Our 
findings suggest that although small in sample size, 
patients with SLE with anxiety or peripheral nerve symp-
toms are significantly and mostly likely to have normal 
structural MRI scans. The findings from our study are pre-
liminary, and more MRI research needs to be done on SLE 
patients with anxiety, autonomic disorder, plexopathy and 
polyneuropathy.
Our study presents with a small number of important 
limitations. First, only a small number of papers reported 
disease activity measure or the time of disease onset to MRI 
evaluation. Similarly, details on treatment were rarely pre-
sented which could have introduced a bias since patients 
may have been given effective treatment before undergoing 
MRI scanning. Another source of bias could have arisen 
from the patient selection in the individual studies. As not 
all NPSLE patients are referred for MRI investigation, it is 
likely that the patients in our analysis may be different in 
terms of disease severity from patients where MRI referral 
was not warranted. There were also limited data provided 
on ethnicity of participants. Other potential sources of bias 
to limit generalisability included the lack of blinding of the 
neuroradiologist reporting the MRI images. Only 26% of 
the studies explicitly stated that appropriate measures were 
taken to ensure minimal bias in this regard. Variations 
between MRI scanner resolutions across the studies may 
have led to inconsistencies in evaluating imaging findings. 
This is difficult to prevent in retrospective designs, which 
in our case consisted of studies published between 1989 
and 2014. Additionally, the introduction of FLAIR imaging 
techniques, which were used only in studies from 2002 
onwards in our study, could have added to a difference in 
the reporting of MRI findings. A potential pitfall in inter-
preting MRI outcomes includes the occurrence of overlap-
ping syndromes for patients presenting with more than one 
NPSLE syndrome. In these cases, it is difficult, if not 
impossible, to reliably ascribe MRI outcomes to a particu-
lar syndrome with certainty. In our study, it was not 
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possible to combine quantitative neuroimaging data due to 
the broad nature of the studies involved. Although the con-
ventional way is voxel or co-ordinate-based meta-analyses 
of neuroimaging data which will identify neuroanatomical 
areas affected by NPSLE, it was not possible to do such 
analyses from the studies we identified. We therefore rec-
ognise that assigning an MRI as either ‘normal’ or ‘abnor-
mal’ has its limitations but was necessary in our study due 
to the wide variability in the data extracted. Finally, our 
review did not exclude studies and analyses based on the 
number of cases of NPSLE evaluated in individual studies. 
This minimised the risk of small sample size publication 
bias from impacting on the review’s findings. However, the 
consequence of this was that for a number of features, such 
as autonomic disorders, demyelinating syndrome and GBS, 
there were very few events included in the analysis, thereby 
presenting under-powered results. As the evidence base 
develops, it is anticipated that further analyses will be 
undertaken to better understand NPSLE.
Conclusion
The results of this article suggest that – despite being the 
current imaging modality of choice in NPSLE – MRI 
should not be used in isolation to make a diagnosis due to 
its inability in some circumstances to differentiate changes 
from non-NPSLE presentations. In the future, the develop-
ment of morphological and metabolic or functional imag-
ing tools could be more useful in early monitoring of 
cerebral involvement, thereby allowing earlier effective 
treatment and improved survival for this population.
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